Heading into 2019, the industry is in for a reckoning with reality, and we’re going to find out how those science projects fare as products, whether biotech’s new generation can actually sell its wares, and if investors’ appetite for risk is as inexhaustible as it has seemed.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,